|Bid||196.71 x 100|
|Ask||208.60 x 100|
|Day's Range||202.60 - 208.50|
|52 Week Range||184.50 - 256.80|
|PE Ratio (TTM)||6.17|
|Dividend & Yield||2.80 (1.30%)|
|1y Target Est||N/A|
If you are a shareholder in Allergan plc’s (NYSE:AGN), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of your portfolioRead More...
The Age-Related Macular Degeneration (AMD) space has been in the spotlight of late due to a number of developments.
Specialty drug maker Allergan (AGN) raised more than a few eyebrows this month when news broke of the deal it made with the Saint Regis Mohawk Tribe of upstate New York to protect patents for one of its blockbuster drugs. In fact, one of Wall Street biggest drug analysts cited the deal as one of three reasons it has downgraded Allergan’s stock and slashed its price target. Allergan decided earlier this month to transfer ownership of the patents protecting the dry eye treatment Restasis, Allergan’s second biggest selling drug, to the tribe to prevent the scrutiny of the U.S. Patent & Trademark Office.